Q3 2019 Data Report

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Back to Publications

Global Landscape

959+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

525North America21Oceania1Africa166Asia13South America233Europe & Israel

Financings

Total Q3 2019 Global Financings

Total Global Financing

$2.6 Billion

 7%

Decrease from Q3 2018

35.7%64.3%0178910111213YTD 2019Full Year 2018

 32%

Decrease year-over-year
$7.4B Raised YTD 2019

Gene & Gene-modified
Cell Therapy

$1.3 Billion

 38%

Decrease from Q3 2018

36.8%63.2%015.566.577.588.599.510YTD 2019Full Year 2018

 30%

Decrease year-over-year
$5.6B raised YTD 2018

Cell Therapy

$1.6 Billion

 13%

Decrease from Q3 2018

30.0%70.0%0133.544.555.566.577.58YTD 2019Full Year 2018

 48%

Decrease year-over-year
$3.3B raised YTD 2019

Tissue Engineering

$40 Million

 327%

Increase from Q3 2018

10.4%89.6%010.10.20.30.40.50.60.70.80.91YTD 2019Full Year 2017

 86%

Decrease year-over-year
$114M raised YTD 2019

Total Global Financings by Type, by Year

38718711151304066819274715159030161237254399510881453682IPOsFollow-OnsCorporatePartnershipsVenture CapitalPrivatePlacement /PIPES0$500m$1,000m$1,500m$2,000m$2,500m$3,000m$3,500m$4,000m$4,500m$5,000m$5,500m$6,000mYTD 2019Full Year 2018Full Year 2017
52611894413542Mergers &Acquisitions0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m$18,000m$20,000m$22,000m$24,000mYTD 2019Full Year 2018Full Year 2017

1052

Clinical trials underway
worldwide by the end of Q3 2018

PH. 1

363

PH. 2

594

PH. 3

95

34.5%56.5%9.0%050100150200250300350400450500550600Phase 1Phase 2Phase 3

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q3 2019

Gene Therapy
31.1%60.3%8.6%020406080100120140160180200220240Phase IPhase IIPhase III
Gene-Modified
Cell Therapy
48.1%48.1%0020406080100120140160180200Phase IPhase IIPhase III
Cell Therapy
18.8%67.4%13.8%02030405060708090100110120130140150Phase IPhase IIPhase III
Tissue Engineering
13.0%50.0%37.0%0681012141618202224Phase IPhase IIPhase III

Clinical Trials by Indication: Q3 2019

Oncology
650
Musculoskeletal
57
Central Nervous System
55
Endocrine Metabolic & Genetic Disorders
51
Cardiovascular
48
Ophthalmology
37
Hematology
33
Immunology & Inflammation
31
Dermatology
22
Infectious Disease
20
Genitourinary Disorders
15
Gastroenterology
15
Respiratory
11
Geriatric Diseases
3
Lymphatic Diseases
2
Surgery
1
Ear Diseases
1

Report Infographics

View Full Report View Past Reports

Alliance for Regenerative Medicine

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

2-4 Schuman Roundabout
B-1040 Brussels
Belgium